Although the long‐term benefit and safety of angiotensin‐converting enzyme (ACE) inhibitors and spironolactone for the treatment of stable CHF has been shown in several studies,10, 11, 12, 13 the safety and ability of these RAAS inhibitors to mitigate diuretic braking during FCRI have not been studied. The gene discussed is ACE; the disease is congestive heart failure.